SYSMHC00007_shraibmanb_160819_admon_Israel_LNT229 | 3 | Human | HLA-A03_01,HLA-B35_01,HLA-C04_01 | ||
SYSMHC00007_shraibmanb_160819_admon_Israel_LNT229D | 3 | Human | HLA-A03_01,HLA-B35_01,HLA-C04_01 | ||
SYSMHC00007_shraibmanb_160819_admon_Israel_T98G | 3 | Human | HLA-A02_01,HLA-B39_06,HLA-C07_02 | ||
SYSMHC00007_shraibmanb_160819_admon_Israel_T98GD | 3 | Human | HLA-A02_01,HLA-B39_06,HLA-C07_02 | ||
SYSMHC00007_shraibmanb_160819_admon_Israel_U87 | 3 | Human | HLA-A02_01,HLA-B44_02,HLA-C05_01 | ||
SYSMHC00007_shraibmanb_160819_admon_Israel_U87D | 3 | Human | HLA-A02_01,HLA-B44_02,HLA-C05_01 |
SYSMHC00007 | SYSMHC00007_shraibmanb_160819_admon_Israel_T98GD | SYSMHC00007_Seq44768_QE2.raw | In vitro | adherent treated with Decitabine | Brain tumor | Glioblastoma-cultured cells | class I | 27412690 | native | Immunoaffinity | W6/32 | Q-Exactive Plus | UltiMate 3000 RSLC | no | DDA | HCD | 5-28% of 100% acetonitrile with 0.1% Formic acid | 120 | 15nl/min | 1 | ||||
SYSMHC00007 | SYSMHC00007_shraibmanb_160819_admon_Israel_T98GD | SYSMHC00007_Seq44769_QE2.raw | In vitro | adherent treated with Decitabine | Brain tumor | Glioblastoma-cultured cells | class I | 27412690 | native | Immunoaffinity | W6/32 | Q-Exactive Plus | UltiMate 3000 RSLC | no | DDA | HCD | 5-28% of 100% acetonitrile with 0.1% Formic acid | 120 | 15nl/min | 2 | ||||
SYSMHC00007 | SYSMHC00007_shraibmanb_160819_admon_Israel_T98GD | SYSMHC00007_Seq44777_QE2.raw | In vitro | adherent treated with Decitabine | Brain tumor | Glioblastoma-cultured cells | class I | 27412690 | native | Immunoaffinity | W6/32 | Q-Exactive Plus | UltiMate 3000 RSLC | no | DDA | HCD | 5-28% of 100% acetonitrile with 0.1% Formic acid | 120 | 15nl/min | 3 |